QoL for CF Patients on Orkambi or Symkevi and for Caregivers in UK

• Research type

  Research Study

• Full title

  Quality of Life for Cystic Fibrosis Patients Treated With Orkambi® or Symkevi® and for Primary Caregivers in the United Kingdom

• IRAS ID

  290795

• Contact name

  Lena Thia

• Contact email

  lena.thia@wales.nhs.uk

• Sponsor organisation

  Vertex Pharmaceuticals

• Clinicaltrials.gov Identifier

  N/A, N/A

• Duration of Study in the UK

  1 years, 9 months, 0 days

• Research summary

  This is a multicenter, longitudinal, and observational study designed to describe the real-world quality of life for patients initiating treatment with Orkambi or Symkevi in the UK from the CF patient- and caregiver-reported perspectives. Data collection will be both prospective and retrospective.

• REC name

  North West - Preston Research Ethics Committee

• REC reference

  20/NW/0461

• Date of REC Opinion

  9 Feb 2021

• REC opinion

  Further Information Favourable Opinion